SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 6
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 6
|
presentations:
1 to
50 of
279
|
UPDATE ON HIV VIROLOGY (ABSTRACT
2001)
Paul Bieniasz
The Rockefeller University, New York, NY, USA
UPDATE ON HIV IMMUNOLOGY (ABSTRACT
2002)
Penelope L. Moore
University of Witwatersrand, Johannesburg, South Africa
UPDATE ON HIV PREVENTION (ABSTRACT
2003)
Sharon L. Hillier
University of Pittsburgh, Pittsburgh, PA, USA
UPDATE ON TUBERCULOSIS TREATMENT AND PREVENTION (ABSTRACT
2004)
Constance A. Benson
University of California San Diego, San Diego, CA, USA
UPDATE ON HIV CURE (ABSTRACT
2005)
Katharine J Bar
University of Pennsylvania, Philadelphia, PA, USA
DISCOVERING THE ART IN SCIENCE (AND MEDICINE): THE HUMAN CONNECTION (ABSTRACT
2)
Dawn Averitt
The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA
FELLOW TRAVELERS: INTERPRETING THE IMPACT OF THE MICROBIOME IN CLINICAL INTERVENTION (ABSTRACT
6)
Adam Burgener
Public Health Agency of Canada, Winnipeg, Canada
MISSING U: HANDLING AND AVOIDING MISSING DATA IN CLINICAL TRIALS (ABSTRACT
7)
Heather Ribaudo
Harvard School of Public Health, Boston, MA, USA
DESIGNING & INTERPRETING HIV PREVENTION TRIALS IN THE ERA OF EFFECTIVE INTERVENTIONS (ABSTRACT
8)
David Dunn
University College London, London, United Kingdom
ENGINEERING THE LATENT RESERVOIR (ABSTRACT
3)
Paula Cannon
University of Southern California, Los Angeles, CA, USA
MORE COLORFUL IMMUNOLOGY: TARGETED ISOLATION OF MONOCLONAL ANTIBODIES (ABSTRACT
5)
Rosemarie Diana Mason
NIAID, NIH, Bethesda, MD, USA
NOVEL IMAGING APPROACHES TO CHARACTERIZE AND QUANTIFY VIRAL RESERVOIRS (ABSTRACT
4)
Jacob D Estes
Oregon Health and Sciences University, Beaverton, OR, USA
HEPATITIS E: CLINICAL CHALLENGES (ABSTRACT
2006)
Sven Pischke
University Hospital Hamburg–Eppendorf, Hamburg, Germany
HEPATITIS D: CLINICAL CHALLENGES (ABSTRACT
2007)
Jeffrey S. Glenn
Stanford University, Stanford, CA, USA
NASH IN HIV (ABSTRACT
2008)
Giada Sebastiani
Chronic Viral Illness Service and Research Institute of McGill University Health Centre, Montreal, Canada
RETREATMENT OF HCV IN ADVANCED LIVER DISEASE (ABSTRACT
2009)
John D Scott
University of Washington, Seattle, WA, USA
SESSION HOST
Richard A. Koup
VRC, NIAID, NIH, Bethesda, MD, USA
ENDING THE HIV EPIDEMIC: A PLAN FOR THE UNITED STATES (ABSTRACT
2010)
Anthony S Fauci
NIH, Bethesda, MD, USA
BERNARD FIELDS LECTURE: DISCOVERY AND DEVELOPMENT OF HIV BROADLY NEUTRALIZING ANTIBODIES (ABSTRACT
10)
Michel Nussenzweig
Rockefeller University, New York, NY, USA
N'GALY-MANN LECTURE: THAILAND'S ACHIEVEMENTS IN HIV TREATMENT, PREVENTION, AND CURE RESEARCH (ABSTRACT
11)
Praphan Phanuphak
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
DENIAL, DOOM, OR DESTINY? RESURGENT STIS IN HIV CARE AND PREVENTION (ABSTRACT
12)
Jeanne M Marrazzo
University of Alabama, Birmingham, USA
INFLAMMATION: TAMING THE FLAMES (ABSTRACT
13)
Irini Sereti
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
HPV VACCINE WITH LEEP DID NOT PREVENT RECURRENT CERVICAL HSIL IN HIV-INFECTED WOMEN (ABSTRACT
14)
Cindy Firnhaber
University of Colorado Medical Center, Aurora, CO, USA
OPTIMAL LUNG CANCER SCREENING CRITERIA AMONG PERSONS LIVING WITH HIV (ABSTRACT
15)
Subhashini A Sellers
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
HIV IS ASSOCIATED WITH DECREASED BREAST CANCER SURVIVAL: A PROSPECTIVE COHORT STUDY (ABSTRACT
16)
Katrin Sara Sadigh
Brigham and Women's Hospital, Boston, MA, USA
LONG-TERM OUTCOMES OF 58 PATIENTS WITH HIV AND KSHV+ MULTICENTRIC CASTLEMAN DISEASE (ABSTRACT
17)
Ramya Ramaswami
HIV AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
REDUCTION OF KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS LATENCY USING CRISPR-CAS9 (ABSTRACT
18)
For Yue Tso
University of Nebraska - Lincoln, Lincoln, NE, USA
THE ROLE OF WILMS' TUMOR 1 IN KAPOSI SARCOMA HERPESVIRUS ONCOGENESIS (ABSTRACT
19)
Ayana Morales
Weill Cornell Medical College, New York, NY, USA
QUANTIFICATION OF KSHV DNA AS A DIAGNOSTIC TEST FOR KAPOSI SARCOMA IN AFRICA (ABSTRACT
20)
Aggrey Semeere
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
TWO NOVEL POTENTIAL THERAPEUTIC TARGETS IN THE KSHV LIFE CYCLE (ABSTRACT
21)
Thomas Schulz
Medizinischen Hochschule Hannover, Hannover, Germany
RANDOMIZED TRIAL OF RALTEGRAVIR-ART VS EFAVIRENZ-ART WHEN INITIATED DURING PREGNANCY (ABSTRACT
39)
Mark Mirochnick
Boston University School of Medicine, Hingham, MA, USA
RCT OF DOLUTEGRAVIR VS EFAVIRENZ-BASED THERAPY INITIATED IN LATE PREGNANCY: DOLPHIN-2 (ABSTRACT
40)
Saye Khoo
University of Liverpool Institute of Translational Medicine, Liverpool, United Kingdom
MATERNAL HBV VIREMIA IS ASSOCIATED WITH ADVERSE INFANT OUTCOMES IN HIV/HBV WOMEN (ABSTRACT
41)
Debika Bhattacharya
University of California Los Angeles, Los Angeles, CA, USA
IMPACT OF IMPROVED NUTRITION/SANITATION ON NEURODEVELOPMENT OF HIV-EXPOSED CHILDREN (ABSTRACT
42)
Robert Ntozini
Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe
UNIQUE IMMUNOLOGICAL AND VIROLOGICAL FEATURES OF EARLY TREATED HIV-INFECTED NEWBORNS (ABSTRACT
43)
Pilar Garcia Broncano
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
NEONATAL ART < 7 DAYS VS 7-28 DAYS REDUCED TIME TO SUPPRESSION (ABSTRACT
44)
Sara Dominguez Rodriguez
Fundación Investigación Biomédica Hospital 12 Octubre, Madrid, Spain
SAFETY AND PHARMACOKINETICS OF MONOCLONAL ANTIBODY, VRC01LS, IN HIV-EXPOSED NEWBORNS (ABSTRACT
45)
Elizabeth J McFarland
University of Colorado School of Medicine, Aurora, CO, USA
BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS (ABSTRACT
46)
Aditya Gaur
St. Jude Children's Research Hospital, Memphis, TN, USA
BREAKING BONES IS BAD: INCIDENT FRACTURE AND MORTALITY IN THE HIV OUTPATIENT STUDY (ABSTRACT
30)
Linda Ann Battalora
Colorado School of Mines, Golden, CO, USA
COPD AND THE RISK FOR MYOCARDIAL INFARCTION BY TYPE IN PEOPLE LIVING WITH HIV (ABSTRACT
31)
Kristina Crothers
University of Washington, Seattle, WA, USA
SUDDEN CARDIAC DEATH AMONG HIV-INFECTED AND -UNINFECTED VETERANS (ABSTRACT
32)
Matthew Freiberg
Vanderbilt University School of Medicine, Nashville, TN, USA
HIV POST SCD STUDY: 80% HIGHER RATE OF AUTOPSY-DEFINED SUDDEN ARRHYTHMIC DEATH IN HIV (ABSTRACT
33)
Zian H. Tseng
UCSF, San Francisco, CA, USA
CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HIV-NEGATIVE INDIVIDUALS: HPTN 077 (ABSTRACT
34)
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
ASSESSING THE PROBIOTIC EFFECT IN TREATED HIV: RESULTS OF ACTG A5350 (ABSTRACT
35)
Edgar Turner Overton
University of Alabama, Birmingham, AL, USA
FACTOR X INHIBITION REDUCES COAGULATION BUT NOT INFLAMMATION IN PERSONS WITH HIV (ABSTRACT
36)
Jason V Baker
Hennepin Healthcare Research Institute (U of MN), Minneapolis, MN, USA
SAFETY, TOLERABILITY AND IMMUNOLOGIC ACTIVITY OF RUXOLITINIB ADDED TO SUPPRESSIVE ART (ABSTRACT
37)
Vincent C. Marconi
School of Medicine, Emory University, Atlanta, GA, USA
INCIDENT SYPHILIS RATES AND PREDICTORS IN US WOMEN WITH HIV, 2005-2016 (ABSTRACT
47)
Jodie Dionne-Odom
University of Alabama at Birmingham, Birmingham, AL, USA
PREPARING FOR PREP IN ENGLAND: PREVALENCE AND INCIDENCE OF HIV AND BACTERIAL STIS (ABSTRACT
48)
Dana Ogaz
Public Health England, London, United Kingdom
EXPANDING TESTING STRATEGIES IN PARIS: A FREE POSTAL COMPREHENSIVE STI TEST KIT (ABSTRACT
49)
Heloise M Delagreverie
Hôpital Saint Louis - APHP, Paris, France
RANDOMIZED CONTROLLED TRIAL OF INTRAUTERINE DEVICE SAFETY IN WOMEN LIVING WITH HIV (ABSTRACT
50)
Catherine S Todd
FHI360, Durham, NC, USA
|
<< first | < prev
page:
of 6
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 6
|
presentations:
1 to
50 of
279
|
